Latest News

  • INVESTMENT

    12 Jan 2026

    Lilly’s Ventyx Deal Points to a Future Beyond Injections

  • MARKET TRENDS

    8 Jan 2026

    Oral Weight Loss Pills Are Shaking Up Metabolic Care

  • PARTNERSHIPS

    6 Jan 2026

    Pfizer’s Metsera Deal Ignites a New Obesity Drug Arms Race

  • RESEARCH

    19 Dec 2025

    Liver-First Drugs Redefine the Next Phase of the MASH Race

FDA Pilot Voucher Signals Faster Reviews for Metabolic Drugs

Business discussion reflecting FDA pilot voucher accelerating metabolic drug reviews

REGULATORY

18 Dec 2025

A new FDA pilot voucher could shrink review timelines for select obesity and diabetes drugs, stirring optimism and debate across the sector

Roche corporate sign in front of modern office building on a clear day

PARTNERSHIPS

25 Nov 2025

Pharma Giants Chase the Next Liver Breakthrough

Novo and Roche spark a US push for new metabolic liver treatments as combo strategies take hold

3D rendering of a metabolic cell structure surrounded by blood components.

INSIGHTS

24 Nov 2025

Beyond GLP1: A New Race to Fix the Body’s Fuel System

OrsoBio pursues deeper metabolic repair beyond GLP-1 drugs, signaling a shift toward long-term health gains; investors should watch emergi...

Wegovy vial and syringe beside a stylized model of metabolic liver and fat cells.

REGULATORY

20 Nov 2025

FDA Nod for Metabolic-Liver Therapy Reshapes Treatment Horizon

FDA expands Wegovy to MASH, potentially expanding the metabolic liver disease market and influencing developer strategy

Red-yellow capsules on a high-tech circuit board symbolizing oral metabolic drug innovation.

PARTNERSHIPS

18 Nov 2025

New Partnership Accelerates Push for Oral Metabolic Breakthroughs

Deep Apple Therapeutics and Novo Nordisk team on a non incretin oral target, stirring new momentum in metabolic research

Novo Nordisk headquarters building symbolizing MASH treatment innovation

INNOVATION

14 Nov 2025

Novo Sparks a New Fight to Fix MASH

Novo’s Akero buy raises the stakes in MASH as investors await key fibrosis data

Close-up illustration of an RNA strand in a biomedical research concept.

INSIGHTS

10 Nov 2025

Lilly’s New RNAi Partner Aims for Two Doses a Year

Eli Lilly and SanegeneBio team up to create long-acting RNAi drugs for obesity and diabetes

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.